| McGlave PB, Xiao OS, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225. van Burik JH and Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematology/Oncology Clinics of North America 1999;13(5): 1065-1089. Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM, Burns LJ, Wagner JE, Eastlund T, Dusenbery K, Weisdorf DJ. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Bone Marrow Transplantation 2000; 26:723-728. Osarogiagbon RU, Defor TE, Weisdorf MA, Erice A, Weisdorf DJ. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biology of Blood and Marrow Transplantation 2000; 6:280-288. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NKC, Wagner J, Enright H: Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplantation. Bone Marrow Transplantation 2000; 26:865-869. Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB, Weisdorf DJ: Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplantation 2000; 26:1173-1177. Weisdorf D, Dharan B, Horowitz M: Transplantation therapy for adults with acute lymphoblastic leukemia: Comparative analysis of autologous and unrelated donor bone marrow transplantation. In: Autologous Blood and Marrow Transplantation, Proceedings of the Tenth International Symposium, July 2000, Dallas, Texas, KA Dicke & A Keating (eds.): Charlottesville, VA, Carden Jennings Publishing Co., Ltd., 380-384, 2001. Burns LJ, Weisdorf DJ, Defor TE, Repka TL, Ogle KM, Hummer C, Miller JS: Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with IL-2 plus G-CSF in patients with advanced breast cancer. Experimental Hematology 2000; 28:96-103. Weisdorf D: Current controversies in bone marrow transplantation. Ann Intern Med 2000; 133:932. Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, Weisdorf D, McGlave P: Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for CML: The U.S. National Marrow Donor Program Experience. Blood 2001; 98:2922-2929. van Burik JA, Lawatsch EJ, DeFor TE, Weisdorf DJ: Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2001; 7: 674-9. Arora M, Wagner JE, Davies SM, Blazar BR, DeFor T, Enright H, Miller WJ, Weisdorf DJ: Randomized clinical trial of thalidomide, cyclosporine and prednisone versus cyclosporine and prednisone as initial therapy of chronic graft versus host disease. Biology of Blood and Marrow Transplantation 2001; 7:265-273. Barker JN, Weisdorf DJ, Wagner JE: Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med 2001; 344:1870-1871. Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, Kurtzberg J, Weisdorf DJ, Wagner JE: Low incidence of epstein-barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biology of Blood and Marrow Transplantation 2001; 7:395-399. Weisdorf D, Anderson, JW, Glick, JH, & Oken, MM: Survival after relapse of low-grade non-Hodgkin’s lympohoma: Implications for marrow transplantation. Classic Papers and Current Comments 2001; 6: 496-502. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NKC, Wagner JE, Blazar BR: Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 2002; 8:40-46. Toor AA, Slungaard A, Hedner U, Weisdorf DJ, Key NS: Post-transplant complications: Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2002; 29:403-408. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99:1971-1977. Barker JN, Davies SM, DeFor TE, Burns LJ, McGlave PB, Miller JS, Weisdorf DJ. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. Br J Haematol 2002; 118:101-7. van Burik JA, Weisdorf DJ. Is it time for a new look at granulocyte transfusions? Transfusion 2002; 42:1393-1395. Anderson, D, Weisdorf, D: Blood vs. Marrow Allogeneic Stem Cell Transplantation. Chapter 8, 103-115. Allogeneic Stem Cell Transplantation: Clinical Research and Practice. Humana Press, Edited by: Mary J. Laughlin, M.D., & Hillard M. Lazarus, M.D., 2003. Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, van Burik JA, Weisdorf DJ. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplantation 2002; 30:945-951. Weisdorf D: Diffuse alveolar hemorrhage: an evolving problem? Leukemia 2003; 17: 1049-1050. Anderson D, Defor T, Burns L, McGlave P, Miller J, Wagner J, Weisdorf D: A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic GVHD and infections. Biol Blood Marrow Transplant 2003; 9:52-59. Dahl E, Burroughs J, DeFor T, Verfaillie C, Weisdorf D: Progenitor content of autologous grafts: Mobilized bone marrow versus mobilized blood. Bone Marrow Transplant 2003; 32:575-80. Arora M, Burns LJ, Davies SM, Macmillan ML, DeFor TE, Miller WJ, Weisdorf DJ: Chronic grave-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003; 9:38-45. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar RB, Burger SR, Panckaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS: IL-2 based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003; 32:177-86. Dudek A, Mahaseth H, Defor T, Weisdorf DJ: Bronchiolitis obliterans in chronic graft versus host disease: Analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplantation 2003; 9:657-666. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan N. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9:512-518. MacMillan ML, Radloff GA, Kiffmeyer WR, DeFor TE, Weisdorf DJ, Davies SM. High producer IL-2 genotype increases risk for acute GVHD after unrelated donor bone marrow transplantation. Transplantation 2003; 76:1758-1762. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan NA. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003; 9:512-518. Weisdorf DJ. Diffuse alveolar hemorrhage: an evolving problem? Leukemia 2003; 17:1049-1050. Koreth R, Weinert C, Weisdorf D, Key N: Measurement of bleeding severity: A critical review. Transfusion. 2004; 44:605-17. Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005; 11:129-35. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005 Jan 4; [Epub ahead of print] Barker JN, Weisdorf DJ, Defor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343-7. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215-22. Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE, Weisdorf DJ. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005; 35: 1133-40. Weisdorf DJ. Chronic graft-versus-host disease: where is promise for the future?
Leukemia 2005; 19: 1532-5. (review). Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-6. Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005; 23: 7032-42. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006; 107: 3804-7. Arora M, Nagaraj S, Witte J, Defor TE, Macmillan M, Burns LJ, Weisdorf DJ. New classification of chronic GVHD: Added clarity from the consensus diagnoses. Bone Marrow Transplant. 2008; [Epub ahead of print] Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2008; 14:1017-1021. Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ.. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-992. Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE, Weisdorf DJ. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14:538-545. Marks DI, Perez WS, He W, Zhang MJ, Biship MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008; 112:426-434. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008; 14:282-289. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 41:635-642. Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D. Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match. Biol Blood Marrow Transplant. 2008; 14: 1334-40. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2008 Oct 22; [Epub ahead of print]. Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. PMID: 19135940 Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009 Jan 12. [Epub ahead of print] PMID: 19139736 Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens. Bone Marrow Transplant. 2008 Dec 22; [Epub ahead of print] PMID: 19104492 Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009 Feb;15(2):214-22. PMID: 19167681 Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with Plerixa for in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15:249-56. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (Allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Feb 9. [Epub ahead of print] PMID: 19204709 Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf EW. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Feb 17. [Epub ahead of print] Bachanova V, Verneris MR, Defor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia (ALL) following reduced intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Jan 28. [Epub ahead of print] PMID: 19179301 Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with Plerixa for in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15:249-56. PMID: 19167685 Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (Allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Feb 9. [Epub ahead of print] PMID: 19204709 Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant. 2009; 15:30-8. PMID: 19135940 Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity. Blood. 2009 Mar 27. [Epub ahead of print] PMID: 19329778 Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 Mar 26.[Epub ahead of print] PMID: 19322205 Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, Devetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 Mar 6. [Epub ahead of print] PMID: 19270260 Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood. 2009 May 14. PMID: 19443659 Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009; 27(22): 3634-41. PMID: 19581540 Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010 Jan;54(1):138-43. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 5;114(19):4293-9. Brunstein CG, Weisdorf DJ. Future of cord blood for oncology uses. Bone Marrow Transplant. 2009 Nov;44(10):699-707. DeFor TE, Majhail NS, Weisdorf DJ, Brunstein CG, McAvoy S, Arora M, Le CT. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant. 2010 May;45(5):933-8. Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transplant. 2010 Feb;16(2):253-62. Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M; Chronic Leukemia Working Committee. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov;15(11):1475-8. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91. Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010 Mar 4;115(9):1850-7. McClune BL, Weisdorf DJ. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol. 2010 Mar;17(2):133-8. Review. Tomblyn M, Young JA, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, Spellman SR, Cooley S, Miller JS, Weisdorf DJ; CIBMTR Infection and Immune Reconstitution Working Committee. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant. 2010 Aug;16(8):1155-61. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):563-4. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010 Apr 10;28(11):1878-87. Thyagarajan B, Lindgren B, Basu S, Nagaraj S, Gross MD, Weisdorf DJ, Arora M. Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations. Biol Blood Marrow Transplant. 2010 Aug;16(8):1084-9. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood. 2010 Jun 17;115(24):5041-52. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011 Jan;46(1):20-6. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010 Jul 1;115(26):5412-7. Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Mar;17(3):300-8. Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, Bornhauser M, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, McCarthy PL, Ratanatharathorn V, Ringdén O, Weisdorf DJ, Rizzo JD. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. Bone Marrow Transplant. 2011 Jan;46(1):34-43. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010 Jul 22;116(3):366-74. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, Khoury HJ, Klumpp T, Koreth J, Lazarus HM, Marks DI, Martino R, Rizzieri DA, Rowe JM, Sabloff M, Waller EK, DiPersio JF, Bunjes DW, Weisdorf DJ. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010 Sep 16;116(11):1839-48. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010 Oct 7;116(14):2411-9. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010 Oct 28;116(17):3129-39; quiz 3377. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, Verneris MR, Appelbaum FR, Wagner JE, Delaney C. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010 Nov 25;116(22):4693-9. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant. 2011 Jul;17(7):1025-32. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011 Feb 24;117(8):2307-18. Weisdorf DJ. How closely related is graft-vs-leukemia to donor/recipient disparity? Best Pract Res Clin Haematol. 2010 Dec;23(4):525-8. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clin Lymphoma Myeloma Leuk. 2010 Dec 1;10(6):458-63. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54. Oran B, Wagner JE, Defor TE, Weisdorf DJ, Brunstein CG. Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2011 Jan 11. [Epub ahead of print] McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res. 2011 Jan 11. [Epub ahead of print] Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ. Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome. Biol Blood Marrow Transplant. 2011 Feb 18. [Epub ahead of print] Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011 Apr 28;117(17):4651-7. Armenian SH, Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant. 2011 Mar 21. [Epub ahead of print] Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2011 Mar 28. [Epub ahead of print] Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011 Jun 16;117(24):6714-20. Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human Herpesvirus 6 Infection after Hematopoietic Cell Transplantation: Is Routine Surveillance Necessary? Biol Blood Marrow Transplant. 2011 Apr 20. [Epub ahead of print] Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant. 2011 May 23. [Epub ahead of print] Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, Dipersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cancer and Leukemia Group B (CALGB). Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60-70 Years with Acute Myeloid Leukemia in First Remission. Biol Blood Marrow Transplant. 2011 Jun 20. [Epub ahead of print] Solh M, Defor TE, Weisdorf DJ, Kaufman DS. Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse. Biol Blood Marrow Transplant. 2011 Jun 12. [Epub ahead of print]
|
